Clinically, cytoplasmic staining of IL-6Rα is significantly correlated with tamoxifen resistance in ER+ breast cancer patients suggesting IL-6/JAK/STAT3 is an actionable therapeutic target to sensitize tumor cells to current SOC treatment (78). This evidence concerns the gene UBXN11 and neoplasm.